2025乳房醫學線上研討會，今年度共3場會議，將於6/27, 7/25, 08/29，在乳e學院線上進行，歡迎有意報考乳房專科醫師的學員及各位會員踴躍上網觀看影片!

CDK4/6 inhibitors and endocrine therapies offer a dual benefit: they block estrogen signaling while also reshaping the TIM. CDK4/6 inhibitors, in particular, have shown promise in triggering anti-tumor immunity and reducing recurrence risk. The presentation primarily discusses clinical management strategies for hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC) after treatment with CDK4/6 inhibitors. 

Although CDK4/6 inhibitors show significant progression-free survival (PFS) benefits in initial treatment, resistance eventually emerges. Post-CDK4/6 inhibitor treatment options for HR+/HER2- mBC include continuing CDK4/6 inhibitor-based regimens, switching to other treatments (such as targeted therapy, PARP inhibitors, chemotherapy, antibody-drug conjugates, etc.), and endocrine therapy. The presentation also discusses the optimal treatment choices after CDK4/6 inhibitor treatment and summarizes the results of several studies.

Besides, the importance of the PI3K-AKT-mTOR pathway in HR+ breast cancer, noting that approximately 40% of HR+/HER2- mBC patients harbor PIK3CA mutations in their tumors, which are associated with a poorer prognosis. PIK3CA mutations are considered truncal mutations in HR+HER2- breast cancer, often occurring early in tumor development and being selected for during tumor progression.

The results of several clinical trials, such as the SOLAR-1 trial, which showed that PI3K inhibitors (like alpelisib) have clinical efficacy in HR+HER2- mBC patients with PIK3CA mutations. Additionally, the BYLieve study evaluated the combination of alpelisib and endocrine therapy in HR+HER2- PIK3CA-mutant mBC patients, demonstrating long-term and very-long-term disease control.

In summary, this presentation provides detailed information on treatment options and strategies for HR+/HER2- mBC patients after CDK4/6 inhibitor treatment, highlighting the significance of PIK3CA mutations and their treatment options.

CDK4/6 inhibitors have emerged as an important treatment option for advanced hormone receptor-positive breast cancer. They work by blocking the activity of proteins called CDK4 and CDK6, which are involved in cell division. By doing this, these inhibitors can prevent cancer cells from growing and dividing.

Several CDK4/6 inhibitors are currently approved for use, including Ribociclib , Palbociclib and Abemaciclib. They are commonly used in combination with hormone therapy as first-line treatment for advanced hormone receptor-positive breast cancer, and have been shown to significantly prolong progression-free survival in this patient population.

It has been observed that certain markers may predict response to treatment, although further research is needed in this area. For example, patients with hormone receptor-positive breast cancer seem to respond better to CDK4/6 inhibitors compared to those with hormone receptor-negative cancer. There is also some evidence to suggest that alterations in certain genes such as PIK3CA could predict resistance to CDK4/6 inhibitors.

Overall, CDK4/6 inhibitors have brought a significant improvement in the management of advanced hormone receptor-positive breast cancer, offering a balance of efficacy and tolerability that can help to optimise patient outcomes.

This course provides an overview of T-DXd reimbursement updates in Taiwan, specifically for HER2+ 2L metastatic breast cancer (mBC) patients and HER2-low, HR- mBC patients under NHIA coverage. It covers policy changes, clinical implications, and eligibility criteria. Additionally, the course highlights T-DXd’s strong efficacy while maintaining a manageable safety profile as an ADC therapy. The session will also explore key adverse event (AE) management strategies, including the prevention and management of nausea and vomiting using three types of antiemetics for high-emetic-risk drugs, and the prevention and management of interstitial lung disease (ILD). The focus will be on proactive monitoring, early intervention, and best practices to optimize patient outcomes.

活動日期：114年10月18日(週六)12:30-17:20(含課前及課後測驗時間)   課程直播過程如有異常請及時洽詢台灣乳房醫學會(02-2523-9118；bcst@ms46.hinet.net)
活動地點：線上直播。
主辦單位：台灣乳房醫學會
指導單位：衛生福利部國民健康署
課程表：課程總表；第六場課表
乳e學院介面操作手冊：請點此下載操作手冊

本堂課程認證學分申請中，如以下：
1.台灣乳房醫學會：5分
2.台灣外科醫學會：1積點
3.台灣醫學會：4.2分
4台灣護理學會：3.6分
5.台灣專科護理師學會：專科護理師2分
6.中華民國醫事放射學會：4.2分
7.中華民國放射線醫學會：1積點
8.中華民國癌症醫學會：腫瘤內科A類3學分、腫瘤外科A類3學分
9.中華民國醫用超音波學會：5分
10.公務人員時數：4小時
11.國民健康署疑異(疑陽)時數：4小時 
12.國民健康署乳篩時數：2小時 (本系列課程共同認列乳篩時數，當年度累積上限為3小時，且共計於年底一併上傳時數，詳細資訊請洽相關單位)

• 備註：
  本乳e學院平台系統中「積分登錄期間」係指學員於該時段完成課程，得獲取時數積分認證資格；「課程開放閱讀期間」係指包含報名、預習、複習等課程開放時段，惟複習等僅作為個人學習，並不包含測驗以及積分認證。
  若欲取得本堂課時數積分，請務必於「積分登錄期間」註記時間內參與並完成課程。

活動日期：114年09月20日(週六)12:30-17:20(含課前及課後測驗時間)   課程直播過程如有異常請及時洽詢台灣乳房醫學會(02-2523-9118；bcst@ms46.hinet.net)
活動地點：線上直播。
主辦單位：台灣乳房醫學會
指導單位：衛生福利部國民健康署
課程表：課程總表；第五場課表
乳e學院介面操作手冊：請點此下載操作手冊

本堂課程認證學分申請中，如以下：
1.台灣乳房醫學會：5分
2.台灣外科醫學會：1積點
3.台灣醫學會：4.2分
4台灣護理學會：3.6分
5.台灣專科護理師學會：專科護理師2分
6.中華民國醫事放射學會：4.2分
7.中華民國放射線醫學會：1積點
8.中華民國癌症醫學會：腫瘤內科A類3學分、腫瘤外科A類3學分
9.中華民國醫用超音波學會：5分
10.公務人員時數：4小時
11.國民健康署疑異(疑陽)時數：4小時 
12.國民健康署乳篩時數： (本系列課程共同認列乳篩時數，當年度累積上限為3小時，且共計於年底一併上傳時數，詳細資訊請洽相關單位)

• 備註：
  本乳e學院平台系統中「積分登錄期間」係指學員於該時段完成課程，得獲取時數積分認證資格；「課程開放閱讀期間」係指包含報名、預習、複習等課程開放時段，惟複習等僅作為個人學習，並不包含測驗以及積分認證。
  若欲取得本堂課時數積分，請務必於「積分登錄期間」註記時間內參與並完成課程。